Irinotecan Hydrochloride Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Irinotecan Hydrochloride Injection (injection) from Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) with status To Be Discontinued. The shortage was first posted on 09/26/2025.
Shortage Details
- Status
- To Be Discontinued
- Company
- Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
- Package NDC
- 25021-230-02
- Dosage Form
- Injection
- Presentation
- Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)
- Initial Posting
- 09/26/2025
- Revised Date